JeffreyELancetMD

Hematologic Oncology

Senior Member, Department Chair - Malignant Hematology Professor of Oncologic Sciences, University of South Florida

Overview of Dr. Lancet

Dr. Jeffrey Lancet is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from SUNY Upstate Medical University and has been in practice 25 years. Dr. Lancet accepts several types of health insurance, listed below. He is one of 170 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He also speaks multiple languages, including Spanish. He has more than 100 publications and over 500 citings.

Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Book by Phone+1(762) 213-1098

Fax+1 813-745-3071

Education & Training

University of RochesterFellowship, Hematology and Medical Oncology, 1996 - 1999
Rochester Regional Health/Unity Hospital (Rochester)Residency, Internal Medicine, 1995 - 1996
University of RochesterResidency, Internal Medicine, 1992 - 1995
SUNY Upstate Medical UniversityClass of 1992

Certifications & Licensure

FL State Medical License Current
FL State Medical License 2004 - 2025
NY State Medical License 1994 - 2006
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation Start of enrollment: 2006 May 01
Terminated
Not Applicable
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase Start of enrollment: 2006 Aug 01
Completed
Phase 1
Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy Start of enrollment: 2006 Aug 01
Completed
Phase 2
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia Start of enrollment: 2007 Nov 15
Completed
Phase 2
Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms Start of enrollment: 2008 Jun 01
Completed
Not Applicable
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients Start of enrollment: 2008 Oct 01
Completed
Phase 2
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) Start of enrollment: 2009 Jun 25
Completed
Phase 1, Phase 2
Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia Start of enrollment: 2011 Apr 06
Terminated
Phase 1
Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Start of enrollment: 2011 May 01
Completed
Phase 2
Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio Start of enrollment: 2011 May 01
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL Start of enrollment: 2012 Mar 30
Active, not recruiting
Phase 2
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
Completed
Phase 3
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib Start of enrollment: 2013 Feb 20
Completed
Phase 1, Phase 2
Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) Start of enrollment: 2013 Aug 29
Completed
Phase 2
A Safety Study of SGN-CD33A in AML Patients Start of enrollment: 2013 Jul 01
Completed
Phase 1
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS Start of enrollment: 2019 May 20
Recruiting
Phase 1
Quality of Life Model for Older Patients With AML Start of enrollment: 2020 Jul 08
Active, not recruiting
CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML Start of enrollment: 2021 Jan 14
Active, not recruiting
Phase 1, Phase 2
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA Start of enrollment: 2021 Mar 30
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

589 citations
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute My...
Jeffrey E. Lancet, Geoffrey L. Uy, Jorge E. Cortes, Laura F. Newell, Tara L. Lin
Journal of Clinical Oncology. 2018-07-19
200 citations
Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study
Nancy K. Gillis, Markus Ball, Qing Zhang, Zhenjun Ma, YuLong Zhao
The Lancet. Oncology. 2017-01-01
280 citations
Acute myeloid leukemia, version 3.2019
Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Frederick R. Appelbaum, Vijaya Raj Bhatt
Journal of the National Comprehensive Cancer Network. 2019-01-01

Journal Articles

Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Ri...
Joshua F Zeidner, Mark R Litzow, Jeffrey E Lancet, Prithviraj Bose, Raoul Tibes, Ivana Gojo, Richard F Little, Judith E Karp, Leukemia Research
A Phase 1 Trial of Vadastuximab Talirine Combined with Hypomethylating Agents in Patients with CD33 Positive AML
Eytan M Stein, Anand Jillella, Anthony S Stein, Amir T Fathi, Roland B Walter, Jeffrey E Lancet, Tibor J Kovacsovics, Anjali S Advani, Phoenix A Ho, Dale Bixby, Blood

Abstracts/Posters

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation
Jeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State
Jeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome
Jeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome
Jeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a
Jeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax
Jeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation
Jeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
Jeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloi...
Jeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Patient Derived Xenografts (PDX) Recapitulate Ruxolitinib Clinical Trial Responses and Identify a Novel Combination Therapy for Chronic Myelomonocytic Leukemia (CMML)
Jeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes
Jeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acu...
Jeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in...
Jeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (_60 Years Old) with Ac...
Jeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients _70 Years with Acute M...
Jeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
Jeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation
Jeffrey E. Lancet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory AnalysisClinically Relevan...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
AML: Expert Guidance on Current Standards and New Directions in Patient Care
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enr...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Novel Therapies for AML: Expanding Future Options
60th American Society of Hematology Annual Meeting - 11/30/2018
The Bad: Secondary Leukemias—How Bad Are They?
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Join now to see all

Authored Content

Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Risk Acute Myeloid Leukemia (AML)August 2018
State of the Art Update and Next Questions: Acute Myeloid LeukemiaOctober 2017

Press Mentions

COVID-19 Takes a Toll on People with Blood Cancers and DisordersDecember 11th, 2021
New AML Approvals Changing the Treatment LandscapeSeptember 8th, 2017
Emerging Agents Poised to Transform AML LandscapeJuly 17th, 2017
Join now to see all

Grant Support

UM-1 North American Star ConsortiumNIH/NCI2020–2026

Professional Memberships

American Society of Hematology - ASH
Member
American Society of Clinical Oncology - ASCO
Member

Other Languages

Spanish

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
Anthem Blue Preferred Plus POS
Anthem KeyCare PPO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Carelink Health Plans PPO
Coventry Florida - Employer Group PPO
Coventry Virginia - HMO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
Network Health Plan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust POS-SE
WEA Trust Preferred Provider Plan - Trust Pref
Please verify your coverage with the provider's office directly when scheduling an appointment